IGM Biosciences to Present at Three Upcoming Investor Conferences

Rhea-AI Summary

IGM Biosciences, a clinical-stage biotechnology firm focusing on IgM antibodies, announced that CEO Fred Schwarzer will participate in several investor conferences. The events include:

• Stifel Healthcare Conference on November 15 in New York
• Jefferies London Healthcare Conference on November 17 in London
• Evercore ISI HealthCONx Conference on December 1 (virtual)

Live webcasts will be available on the Company’s website and will remain archived for 90 days post-event.

MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences:

• Stifel Healthcare Conference on Tuesday, November 15 at 9:45 a.m. EST in New York
• Jefferies London Healthcare Conference on Thursday, November 17 at 9:45 a.m. GMT/ 4:45 a.m. EST in London
• Evercore ISI HealthCONx Conference on Thursday, December 1 at 10:30 a.m. EST (virtual)
  

A live webcast of the events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.

About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, infectious diseases and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information, please visit www.igmbio.com.

Contact
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

What conferences will IGM Biosciences participate in during November and December 2022?

IGM Biosciences will participate in the Stifel Healthcare Conference on November 15, Jefferies London Healthcare Conference on November 17, and the Evercore ISI HealthCONx Conference on December 1, 2022.

What time will the Stifel Healthcare Conference start for IGM Biosciences?

The Stifel Healthcare Conference for IGM Biosciences is scheduled to start at 9:45 a.m. EST on November 15, 2022.

How can I watch the IGM Biosciences investor conference webcasts?

The webcasts of the IGM Biosciences investor conferences will be available on the Company’s 'Events and Presentations' page on their website.

How long will the webcasts for IGM Biosciences be available after the conferences?

The webcasts for IGM Biosciences will be archived on the Company’s website for 90 days following the presentations.

What is the focus of IGM Biosciences' research?

IGM Biosciences focuses on developing IgM antibodies for cancer, infectious diseases, and autoimmune and inflammatory diseases.